Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (629)	3/26/1999 12:11:00 PM
From: R. Ramesh	Respond to of 942

Should be an interesting day. WLA up very strong this morning after selling off a little at the opening. We will know the real deal next week. Only to crash down to 65+. I blame the news release. They are reiterating the same thing as if it is new. Some one wants this low. Ramesh

To: Brian Malloy who wrote (629)	3/26/1999 6:18:00 PM
From: Sonki	Respond to of 942

AFTER THE BELL - Warner-Lambert moves up NEW YORK, March 26 (Reuters) - Warner-Lambert Co. rose in Friday's post-session after news that a U.S. Food and Drug Administration advisory panel endorsed continued use of the diabetes drug Rezulin. The panel recommended that Rezulin be used with older diabetes drugs and not as a monotherapy. Rezulin has been linked to liver problems including some fatalities. Warner-Lambert traded at 69-1/2 in after-hours activity, up 1-13/16 from the regular close. The New York Stock Exchange said volume in after-hours session one was 1,006,300 shares compared to 1,392,800 on Thursday. Volume in session two was 16,294,241 shares versus 5,212,928 on Thursday.